Chromosomal Translocations as a Mechanism of BRAF Activation in Two Cases of Large Congenital Melanocytic Nevi  by Dessars, Barbara et al.
Chromosomal Translocations as a Mechanism of
BRAF Activation in Two Cases of Large Congenital
Melanocytic Nevi
Barbara Dessars1,6, Linda E. De Raeve2,6, Hakim El Housni3, Catherine J. Debouck3, Pierre J. Sidon1,4,
Renato Morandini5, Diane Roseeuw2, Ghanem E. Ghanem5, Gilbert Vassart1 and Pierre Heimann3,4
Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS or
BRAF through point mutations. In two cases of large congenital melanocytic nevi, we observed a chromosomal
translocation involving the BRAF oncogene on chromosome 7q34, resulting in both cases in removal of the
auto-inhibitory N-terminal regulatory domain (hence the Ras-guanosine triphosphate binding domain) of BRAF
from its protein kinase domain. This is early evidence of BRAF activation through chromosomal translocation in
melanocytic tumors. Because BRAF point mutations are rather rare in congenital melanocytic nevi and
melanoma arising in non-sun-exposed area, the molecular mechanism of oncogenic activation as described
here could be a recurrent molecular feature in these groups of melanocytic tumors.
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INTRODUCTION
Although studies report an increased risk of melanoma in
large congenital melanocytic nevi (LCMN), genetic investiga-
tions are rather rare in this type of melanocytic lesion (Berg
and Lindelof, 2003; Ichii-Nakato et al., 2006). Here we
describe involvement of the BRAF oncogene through
chromosomal translocation in two cases of LCMN.
RESULTS AND DISCUSSION
Cytogenetic analysis demonstrated a 46, XX, t(5;7)(q31;q34)
[20] karyotype in case 1, and a 46, XY, t(2;7)(q24q33;
q33q36) [20] karyotype in case 2 (Figure 1). Constitutional
karyotypes were normal in both patients. Fluorescence in situ
hybridization (FISH) analysis performed in both cases
revealed splitting of the bacterial artificial chromosome
RP11-25N5 (Figure 1), demonstrating the involvement of
the BRAF gene in chromosomal translocation. Subsequent
hybridizations with the bacterial artificial chromosome/P1
artificial chromosome – RP4-726N20 and RP5-839B19 – as
well as with ‘‘home-made’’ probes (see Table S1) spanning
the Ras-guanosine triphosphate binding domain (RBD) and
protein kinase domain (PKD) of BRAF further delineated
the breakpoint region between the PKD (remaining on the
derivative chromosome 7) and the RBD (translocated to the
derivative chromosome 5 in case 1 and to the derivative
chromosome 2 in case 2) (data not shown). 50 Rapid
amplification of cDNA ends-PCR was performed in patient
1 using the 50 rapid amplification of cDNA ends-PCR assay
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions (see Table S1), and revealed a hybrid sequence
including the 50 part of the FCHSD1 gene and the 30 part of
the BRAF gene, with a junction between FCHSD1 exon 13
and BRAF exon 9. Reverse transcriptase-PCR confirmed the
existence of the FCHSD1-BRAF fusion transcript using 50
FCHSD1 and 30 BRAF primers (Figure 1), and showed the
presence of the whole BRAF PKD included in its 30 part (see
Table S1 for primers used and Figure S1 for the fusion
transcript cDNA and predicted amino-acid sequences). In
case 2, no chimeric sequence could be identified either by 50
rapid amplification of cDNA ends-PCR or by large genomic
PCR. Western blots of lysates from cultured cells of patients 1
and 2 revealed increased phosphorylation of extracellular
signal-regulated kinase 1/2 (p44/42 mitogen-activated
protein kinase (MAPK)) compared with normal melanocytes
(Figure 1), demonstrating activation of the MAPK pathway in
these samples. In order to rule out the putative participation
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of BRAF and RAS point mutations in this MAPK pathway
activation, sequencing of exons 11–17 of the BRAF gene, the
whole NRAS coding sequence, and exons 1–4 of KRAS and
2–4 of HRAS genes (regions known to harbor all described
mutations of these four genes in melanocytic tumors) was
performed and failed to show any mutation (see Table S1).
We are thus dealing with two cases of LCMN presenting a
novel mechanism of BRAF gene alteration. BRAF protein is one
of the effectors belonging to the MAPK pathway and is
composed of three functional domains conserved within the
rapidly accelerated fibrosarcoma (RAF) kinase family: CR1 and
CR2 in the N-terminal region, and CR3 in the C-terminal
region. The CR1 domain includes the RBD, which mediates
RAS binding, triggering the recruitment of BRAF protein to the
cell membrane, and its kinase activation, whereas the CR3
domain contains the PKD (Mercer and Pritchard, 2003). In
patient 1, t(5;7)(q31;q34) translocation resulted in the fusion of
the 50 part of the FCHSD1 gene to the 30 part of the BRAF gene
on derivative chromosome 7. Although the exact function of
the FCHSD1 gene is still undetermined, the protein is known to
be characterized by an FER/CIP4 homology (FCH) domain
located in its N-terminal portion and two SH3 domains in its C-
terminal portion (Katoh and Katoh, 2004). FCH domains are
involved in the regulation of cytoskeletal rearrangements
(Aspenstro¨m, 1997), whereas SH3 domains are described as
protein-interaction modules playing critical roles in a wide
variety of biological processes by binding to proline-rich
ligands (Mayer, 2001). The hybrid protein generated by the
chimeric gene thus contains the FCH domain of FCHSD1 in its
N-terminal part, and the PKD domain of BRAF in its C-terminal
portion, with loss of the auto-inhibitory RBD domain.
In patient 2, the chimeric gene generated by the
t(2;7)(q24q33;q33q36) translocation could not be determined
despite several PCR attempts, but FISH results allowed us to
assume that the same molecular alteration of the BRAF gene
was present in this case, hence the removal of the auto-
inhibitory RBD domain from its PKD domain.
It has been demonstrated that removal of the N-terminal
regulatory domain of the RAF gene results in a kinase domain
with high basal activity independent of RAS activation
(Chong and Guan, 2003). Although uncommon, an onco-
genic fusion transcript involving BRAF has also been reported
in thyroid papillary carcinoma (Ciampi et al., 2005). This
fusion transcript resulted from a paracentric inversion of
chromosome 7 and was composed of the 50 part of the
AKAP9 gene (exons 1–8) and the 30 part of BRAF (exons 9–18),
including its PKD domain. Interestingly, the hybrid protein,
for which increased kinase activity as well as transforming
properties were demonstrated, had lost the BRAF auto-
inhibitory N-terminal portion, as observed in our two cases.
Thus, the release of the BRAF PKD domain from its auto-
inhibitory domain seems to be the common point between
our two cases and those reported by Ciampi et al. (2005). The
gene partners are different in each situation and probably
have no fundamental role in the BRAF activation generated
by the translocation. The role of the partner gene may be
limited to providing an efficient promoter driving the
expression of constitutively activated BRAF.
In the present cases, the mitotic events generating the
translocations would have to have occurred relatively early in
embryogenesis to produce such LCMN. These events would
arise from error-prone non-homologous end-joining repair of
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Figure 1. BRAF alterations in both cases studied. (a) Partial G-banding karyotype in patient 1 showing t(5;7)(q31;q34). (b) Partial G-banding karyotype in
patient 2 showing t(2;7)(q24q33;q33q36). (c) Metaphase FISH of patient 1 showing splitting of the RP11-25N5 bacterial artificial chromosome (spectrum orange)
with signals on both derivative (arrowhead) and normal chromosomes 7 and on the derivative chromosome 5 (arrow). Both normal and derivative chromosomes
7 and 5 were identified by Alpha CEP7 (spectrum green) and TelVysion 5p (spectrum green) probes, respectively. (d) Metaphase FISH in patient 2 showing
splitting of the RP11-25N5 bacterial artificial chromosome (spectrum orange) with signals on both derivative (arrowhead) and normal chromosomes 7, and on
the derivative chromosome 2 (arrow). Both normal and derivative chromosomes 7 and 2 were identified by Alpha CEP7 (spectrum green) and Alpha CEP2
(spectrum aqua) probes, respectively. (e) Sequence of the cDNA breakpoint junction in patient 1, showing partial FCHSD1 and BRAF sequences in the 50 and 30
parts of the junction, respectively. (f) Western blots from normal melanocytes, and from tumoral melanocytes of patients 1 and 2, after 24 hours of serum
depletion in the cell culture medium. A high basal activation of the MAPK pathway was observed in both patients 1 and 2, compared to normal melanocytes.
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double-strand breaks in DNA (Xiao et al., 2001). Transloca-
tions of chromosome 7 with either chromosome 5 or
chromosome 2 in our two patients may be not fortuitous
but, rather, related to their proximity to interphase melano-
cytic nuclei, as described for other tumor-associated chro-
mosomal translocations (Neves et al., 1999).
The apparently rare occurrence of chromosomal translo-
cations involving BRAF in melanocytic tumors could be the
result of the small number of reported studies dealing with
karyotype analyses in this type of neoplasia. On the other
hand, point mutations (especially the BRAFV600E mutation)
are the main molecular mechanism of BRAF activation in
both benign and malignant acquired melanocytic tumors
(Davies et al., 2002; Pollock et al., 2003). However, BRAF
mutations are rarer in medium CMN and LCMN (De Raeve
et al., 2006; Ichii-Nakato et al., 2006). It may be that
translocations involving BRAF represent an alternative
mechanism of its activation in CMN that harbor neither a
BRAF nor an NRAS mutation and in melanoma from
chronically sun-exposed or non-sun-exposed skin (for which
BRAF mutations are also rare, as noted in medium CMN and
LCMN). Other karyotypic studies on CMN and other
melanomas are needed to corroborate this hypothesis.
MATERIALS AND METHODS
Primary melanocytic cell cultures were performed from tumoral
samples as described previously (Morandini et al., 1998). Informed
consent was obtained from the patients, and the study was approved
by the Ethical Committee of the Faculty of Medicine (Universite´
Libre de Bruxelles). The study was conducted according to the
Declaration of Helsinki Principles. For both cases, G-banding
karyotypes were expressed according to the International System
for Human Cytogenetic Nomenclature (1995). FISH was performed
with BAC/PAC (supplied by Archives Group at the Sanger Institute,
Cambridge, UK) labelled using the Vysis Nick Translation Kit
(Downers Grove, IL). The different PCR primers as well as PCR
protocols used are detailed in Table S1. Western blotting analyses
were performed on proteins lysates from normal and tumoral
melanocytes after 24 h of serum depletion. These experiments were
reproduced on two independent lysates for each patient and
performed with anti-phospho-p44/42 MAPK (Cell Signaling Tech-
nology, Beverly, MA) or anti-total ERK2 (extracellular signal-
regulated kinase 2) antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA).
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SUPPLEMENTARY MATERIAL
Table S1. List of forward and reverse primers and respective PCR conditions
used to make FISH probes, to perform 50 rapid amplification of cDNA ends-
PCR and reverse transcriptase-PCR investigations, and for BRAF, NRAS,
HRAS, and KRAS genes sequencing.
Figure S1. FCHSD1-BRAF fusion cDNA sequence and predicted amino-acid
sequence for patient 1.
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